Glucose Management and Statin Therapy

Slides:



Advertisements
Similar presentations
The Latest Lipid Guidelines:
Advertisements

Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Statin Selection in the Elderly
Optimizing Statin Therapy
LDL Established Target for Cardiovascular Risk
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Statin Selection Aimed to Reduce New-Onset DM Risk:
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Select Topics in Cardiovascular Medicine
American Heart Association Scientific Sessions
Obesity and Dyslipidemia: How Would You Treat?
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Statins and the Elderly Patient
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Understanding Statin Metabolism
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Statin Class in Session
Diabetes Increases Risk of CVD
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
What's New in Dyslipidemia?
Statins and Glucose Metabolism: Are All Agents Alike?
Statin Class in Session
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Personalizing Statin Therapy in Patients With HIV
A Journal Club on Lipid Management:
PCSK9 Inhibitors and Cardiovascular Outcomes
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
Improving Appropriate Access to PCSK9 Inhibitors
Statins and HIV:.
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Lipid Clinic Challenge
Clinicians' Corner in Dyslipidemia
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
Statins, Obesity, and Hyperlipidemia
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
A Family Affair.
New Lipid-Lowering Guidelines
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Statins and Glucose Metabolism: An Endocrinology Perspective
CHD RISK Glycemia 75g OGTT Time Metabolic Syndrome
Glucose Management and Statin Therapy
Updates on Dyslipidemia
Achieving Lipid Targets With PCSK9 Inhibition
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Statin Selection in Patients With Pre-Diabetes: Case Considerations
Statin Therapy in Patients With Insulin Resistance
in diabetic patients with mixed dyslipidemia
Fresh perspectives ON BASAL Insulins in diabetes care
The Challenge of Insulin Titration
Presentation transcript:

Glucose Management and Statin Therapy

Program Goals

Patient Case

Risk of Developing New-Onset Diabetes: Meta-Analysis of Placebo-Controlled Statin Trials

JUPITER Trial: Effect of Statin Therapy in Patients at High Risk of Developing Diabetes

LIVES Study

J-PREDICT: Effect of Pitavastatin on the Incidence of Diabetes

Observational Studies: Effects of Statins on Risk of Developing Diabetes

How Statins Could Impair Glucose and Insulin Metabolism

Genetics of HMGCR AND PCSK9 Suggest New-Onset Diabetes is On-Target Effect

Weight Gain Associated With Statin Therapy

Risk of New-Onset Diabetes With Pitavastatin

NLA Recommendations for Managing Dyslipidemia

Changes in LDL-C and Glycemia in Head-to-Head Statin Trials

Role of PCPs in Managing Dyslipidemia

Take-Home Messages

Abbreviations

Abbreviations (cont)